{"id":11937,"date":"2026-11-11T18:03:02","date_gmt":"2026-11-11T12:33:02","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-11\/"},"modified":"2026-11-11T18:03:04","modified_gmt":"2026-11-11T12:33:04","slug":"auropharma-share-price-today-2026-11-11","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-11\/","title":{"rendered":"Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 1.50% | 11 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: AUROPHARMA<\/strong> \u00b7 11 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,827.50<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-1.50%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,859.90 \/ \u20b91,807.00<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,855.30<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>23.99 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>11 November 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Aurobindo Pharma Ltd shares declined 1.50% on Tuesday, closing the session at \u20b91,827.50 after moving between an intraday high of \u20b91,859.90 and a low of \u20b91,807.00.<\/li>\n<li>Aurobindo Pharma announced that Apitoria Unit 2, an API manufacturing facility operated by its wholly owned subsidiary Apitoria Pharma Private Limited in Telangana, received an Establishment Inspection Report from the US FDA. The inspection, conducted between September 7 and September 15, 2026, concluded with the facility being classified as Voluntary Action Indicated.<\/li>\n<li>Trading volume was 2.10 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Aurobindo Pharma share price falling on 11 November 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Aurobindo Pharma Ltd shares declined 1.50% on Tuesday, closing the session at \u20b91,827.50 after moving between an intraday high of \u20b91,859.90 and a low of \u20b91,807.00.<\/p>\n<p class=\"wt-copy\">The broader market demonstrated positive momentum as the Nifty benchmark advanced 0.84%, whereas the sector-specific Nifty Pharma index slipped 0.41%. Aurobindo Pharma&#x27;s negative price performance underperformed both the headline index and its sectoral peer group, retreating from recent multi-session gains that included a 3.07% return in the prior session and a 3.94% return over two sessions, alongside a 7.85% gain over the preceding five trading days.<\/p>\n<p class=\"wt-copy\">The stock&#x27;s movement coincides with recent company developments, including an Establishment Inspection Report received by subsidiary Apitoria Pharma from the US FDA classifying its Unit 2 facility as Voluntary Action Indicated, alongside recent corporate restructuring and interim dividend record dates. While these operational milestones provide backdrop context for the pharmaceutical major, today&#x27;s price pullback reflects profit-taking and technical retracement following a strong run-up over the past week.<\/p>\n<p class=\"wt-copy\">23.99 lakh shares traded by 11 November 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 11.44 lakh shares (2.10 times). The five-day average daily volume was 20.54 lakh shares. Separately, the NSE report for 11 November 2026 showed 14.09 lakh shares delivered, representing 58.73% of that day\u2019s traded volume. The same report recorded 82,528 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>profit-taking after recent strength amid higher-than-average volume<\/strong><\/p>\n<p class=\"wt-copy\">The stock retreated 1.50% on heavy volume following a strong multi-day advance that saw gains of over 7% across the preceding five trading days. No single negative catalyst was reported, pointing to routine profit-taking and technical positioning.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">US FDA Inspection Classification for Apitoria Unit 2<\/div>\n<div class=\"wt-card-date\">11 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Aurobindo Pharma announced that Apitoria Unit 2, an API manufacturing facility operated by its wholly owned subsidiary Apitoria Pharma Private Limited in Telangana, received an Establishment Inspection Report from the US FDA. The inspection, conducted between September 7 and September 15, 2026, concluded with the facility being classified as Voluntary Action Indicated.<\/p>\n<p class=\"wt-copy\">A Voluntary Action Indicated classification confirms regulatory compliance and closes the inspection cycle without escalating enforcement measures, supporting ongoing manufacturing operations.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_11112026112206_LtrToSEsApitoriaUnit2USFDA11112026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Interim Dividend Record Date and Payment<\/div>\n<div class=\"wt-card-date\">5 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The board of directors approved an interim dividend of 700%, amounting to \u20b97.00 per equity share of Re 1 face value for the financial year 2026-27. The company set November 11, 2026, as the record date for determining eligible shareholders, with payouts scheduled on or before November 20, 2026.<\/p>\n<p class=\"wt-copy\">The dividend distribution provides direct cash returns to shareholders and establishes a key capital return milestone for the current financial year.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Restructuring and Subsidiary Merger Proposal<\/div>\n<div class=\"wt-card-date\">5 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The board approved a scheme of amalgamation to merge Auroactive Pharma Private Limited into Apitoria Pharma Private Limited, both wholly owned subsidiaries of the company. Additionally, the company approved transferring ownership of step-down subsidiary Auro Pharma LLC in Russia from Auro Active Pharma to Auropharm Overseas Limited for a cash consideration of approximately \u20b929 crores.<\/p>\n<p class=\"wt-copy\">These internal corporate restructuring initiatives streamline group operations, consolidate API manufacturing entities, and optimize overall corporate holding structures.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">General Updates<\/div>\n<div class=\"wt-card-date\">11 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Aurobindo Pharma Limited has informed the Exchange that Apitoria Unit 2, an API manufacturing facility of Apitoria Pharma Private Limited., a subsidiary of the Company, receives Establishment Inspection Report from US FDA with classification as Voluntary Action Indicated<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_11112026112206_LtrToSEsApitoriaUnit2USFDA11112026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Aurobindo Pharma arm gets &#x27;Voluntary Action Indicated&#x27; classification for Telengana facility from USFDA &#8211; The Economic Times<\/div>\n<div class=\"wt-card-date\">11 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Aurobindo Pharma arm gets &#x27;Voluntary Action Indicated&#x27; classification for Telengana facility from USFDA The Economic Times<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_11112026112206_LtrToSEsApitoriaUnit2USFDA11112026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">51.88%<\/div>\n<div class=\"wt-note\">51.88% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">17.41%<\/div>\n<div class=\"wt-note\">16.38% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">41.83%<\/div>\n<div class=\"wt-note\">41.48% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1737425_14102026114826_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.31% on 30 September 2026. This compares with 16.71% on 30 June 2026, a change of -0.40 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 44 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">QUANT MUTUAL FUND &#8211; QUANT ARBITRAGE FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.83 crore shares \u00b7 4.91%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">SBI NIFTY MIDCAP 150 INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.02 crore shares \u00b7 3.51%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC MUTUAL FUND-HDFC ARBITRAGE FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.85 crore shares \u00b7 3.22%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1737425_14102026114826_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Research &amp; Brokerage Views<\/h2>\n<div class=\"wt-grid wt-grid-brokerage\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Nuvama<\/div>\n<div class=\"wt-card-date\">23 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-broker-facts\"><span><span class=\"wt-label\">Rating<\/span><strong>Buy<\/strong><\/span><\/div>\n<p class=\"wt-copy\">Maintained a positive outlook on the stock following steady operational progress and expanding market positioning in the pharmaceutical sector.<\/p>\n<div class=\"wt-note wt-source-note\">Attributed brokerage opinion; not a WittyTrades recommendation.<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution of the approved merger between Auroactive Pharma and Apitoria Pharma<\/li>\n<li>Progress on international regulatory compliance and US FDA facility audits<\/li>\n<li>Delivery volume trends relative to the 20-day average volume of 2.1x<\/li>\n<li>Management commentary during upcoming investor and analyst meetings<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-09\/\">Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 2.84% | 9 November 2026 \u2014 9 November 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-05\/\">Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 4.69% | 5 November 2026 \u2014 5 November 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-10-23\/\">Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 2.43% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/auropharma\/\">More Aurobindo Pharma news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Aurobindo Pharma company news?<\/h3>\n<p class=\"wt-copy\">Aurobindo Pharma announced that Apitoria Unit 2, an API manufacturing facility operated by its wholly owned subsidiary Apitoria Pharma Private Limited in Telangana, received an Establishment Inspection Report from the US FDA. The inspection, conducted between September 7 and September 15, 2026, concluded with the facility being classified as Voluntary Action Indicated.<\/p>\n<h3>How strong was Aurobindo Pharma\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">23.99 lakh shares traded, 2.10 times the 20-day average daily volume. The price and volume data are dated 11 November 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-11\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/auropharma-share-price-today-2026-11-11\/\"}, \"headline\": \"Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 1.50% | 11 November 2026\", \"description\": \"Aurobindo Pharma share price fell 1.50% to \u20b91,827.50 today. See why AUROPHARMA is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-11-11T18:02:53.004463+05:30\", \"dateModified\": \"2026-11-11T18:02:53.004463+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Aurobindo Pharma\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"AUROPHARMA\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/auropharma-company-news-2026-11-11.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"General Updates\",\"summary\":\"Aurobindo Pharma Limited has informed the Exchange that Apitoria Unit 2, an API manufacturing facility of Apitoria Pharma Private Limited., a subsidiary of the Company, receives Establishment Inspection Report from US FDA with classification as  Voluntary Action Indicated\",\"source\":\"NSE\",\"published\":\"11-Nov-2026 11:29:06\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_11112026112206_LtrToSEsApitoriaUnit2USFDA11112026.pdf\",\"disclosure_text\":\"Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83\/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad \u2013 500 032, Telangana, India. Tel : +91 40 6672 5000 \/ 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370\/ 2374 7340 Fax: +91 40 2374 1080 \/ 2374 6833 November 11, 2026 To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA To The Corporate Relations Department BSE LIMITED Phiroze Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804 Dear Sir\/Madam, Sub: Apitoria Unit 2, an API manufacturing facility of Apitoria Pharma Private Limited., a subsidiary of the Company, receives Establishment Inspection Report from US FDA with classification as \u201cVoluntary Action Indicated\u201d \u2013 Reg., Ref: Our letter dated September 15, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that: The United States Food and Drug Administration (US FDA) inspected Unit -II, an API manufacturing facility of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company, situated at Gaddapotharam, Industrial Development Area \u2013 Kazipally Indust rial Area, Jinnaram Mandal, Sangareddy District, 502319, Telangana from September 7th to September 15th, 2026. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as \\\"Voluntary Action Indicated\\\" (\\\"VAI\\\"). FDA has concluded that this inspection is closed under 21 CFR 20.64(d)(3). Please take the above information on record. Thanking you, Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary\"},{\"title\":\"Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDA - The Economic Times\",\"summary\":\"Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDA The Economic Times\",\"source\":\"The Economic Times\",\"published\":\"Wed, 11 Nov 2026 08:52:21 GMT\",\"source_type\":\"business media\",\"generic_watchlist\":false}],\"recent_news\":[{\"summary\":\"a press release dated November 04, 2026, titled \\\"Press release on Q2 FY27 Financial Results.\\\".\",\"category\":\"Press Release\",\"date\":\"04-Nov-2026 20:09:09\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026200852_LtrToSEsPressRelease04112026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"04-Nov-2026 19:53:46\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026194825_LtrToSEsOutcomeOfBM04112026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company.\",\"category\":\"Acquisition\",\"date\":\"04-Nov-2026 20:31:29\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_04112026203119_LtrToSEsOwnershipTransferRussia04112026.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":5},{\"summary\":\"a press release dated October 03, 2026, titled \\\"Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg\\\".\",\"category\":\"Press Release\",\"date\":\"03-Oct-2026 17:03:34\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/AUROPHARMA_03102026170252_LtrToSEsPressReleasePerampanelUSFDAapproval03102026.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"promoter_pledge\":{\"summary\":\"The promoter\/promoter-group disclosure states that the shares covered by the filing were free from encumbrance.\",\"events\":[{\"summary\":\"UMBAI-400 051 Company Code No. AUROPHARMA Dear Sir I Madam, To The Corporate Relations Department SSE LIMITED Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI-400 001 Company Code No. 524804 Sub: Disclosure of encumbrance pursuant to Reg. 31(4) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Pursuant to the applicable provisions of Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, I, K. Nithyananda Reddy, one of the Promoters of the Company and on behalf of the other promoter and Promoter Group of the Company hereby declare that we have not made any encumbrance, directlyor indirectly, on the shares held by us in Aurobindo Pharma Limited, other than those already disclosed to the Stock Exchanges during the financial year ended on March 31,2026. I am enclosing herewith the list of promoters and promoter group of Aurobindo Pharma Limited without PAN as on March 31, 2026 Please take the information on record . Thanking you, Yours faithfully, \\\\L. __ - II K. NITHYANANDA REDDY AUTHORISED SIGNATORY (PROMOTRS & PROMOTER GROUP-AUROBINDO PHARMA LIMITED) Plot No 75 and 76, Huda EncLave B, Nandagiri Hills Jubilee Hi\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"19-Jun-2026 16:03:17\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_bbodade_11052026184659_AUROPHARMA.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":51.88,\"public_pct\":48.12,\"fii_pct\":17.41,\"dii_pct\":24.42,\"mf_pct\":16.31,\"institutional_pct\":41.83,\"noninst_pct\":6.29,\"mf_scheme_count\":44,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"QUANT MUTUAL FUND - QUANT ARBITRAGE FUND\",\"shares\":28265663,\"pct\":4.91},{\"name\":\"SBI NIFTY MIDCAP 150 INDEX FUND\",\"shares\":20175334,\"pct\":3.51},{\"name\":\"HDFC MUTUAL FUND-HDFC ARBITRAGE FUND\",\"shares\":18548115,\"pct\":3.22}],\"period\":\"30-SEP-2026\",\"submission_date\":\"14-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1737425_14102026114826_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":51.88,\"previous_fii_pct\":16.38,\"previous_dii_pct\":25.1,\"previous_mf_pct\":16.71,\"previous_institutional_pct\":41.48,\"previous_mf_scheme_count\":42,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"brokerage_views\":[{\"brokerage\":\"Nuvama\",\"rating\":\"Buy\",\"target\":null,\"view_summary\":\"Aurobindo Pharma shares up 25% in 2026: Nuvama says 'Buy', ups target price; here's why Business Today\",\"headline\":\"Aurobindo Pharma shares up 25% in 2026: Nuvama says 'Buy', ups target price; here's why\",\"published\":\"2026-06-23T07:00:00+00:00\",\"source\":\"Business Today\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo Pharma share price fell 1.50% to \u20b91,827.50 today. See why AUROPHARMA is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":11936,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 1.50% | 11 November 2026","_witty_meta_description":"Aurobindo Pharma share price fell 1.50% to \u20b91,827.50 today. See why AUROPHARMA is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"Aurobindo Pharma share price today","_witty_reason_label":"profit-taking after recent strength amid higher-than-average volume","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[89],"class_list":["post-11937","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-auropharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=11937"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11937\/revisions"}],"predecessor-version":[{"id":11938,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11937\/revisions\/11938"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/11936"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=11937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=11937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=11937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}